However, CMT2 was enriched in pathways including (1) malignant tumors such as melanoma and glioma; (2) pathways related to tumor progression, such as the mTOR signaling pathway, MAPK signaling pathway and JAK-STAT signaling pathway; and (3) immune cell infiltration and cell adhesion (Fig. 3A). This evidence concerns the gene MTOR and glioma.